Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Jul 2016

Drilon A, Bergagnini I, Delasos L, Sabari J, Woo K M, Plodkowski A, Wang L, Hellmann M D, Joubert P, Sima C S, Smith R, Somwar R, Rekhtman N, Ladanyi M, Riely G J, Kris M G

Abstract excerpt

BACKGROUND: RET rearrangements are targetable, oncogenic lung cancer drivers. While previous series have shown durable clinical benefit with pemetrexed-based therapies in ALK- and ROS1-rearranged lung cancers, the benefits of pemetrexed-based treatments in patients with RET-rearranged lung cancers relative to other genomic subsets have not previously been explored. PATIENTS AND METHODS: A retrospective review of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Disease-Free Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Rearrangement

Share to Pemetrexed

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins c-ret

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor Protein-Tyrosine Kinases

Source

Open in PubMed Open full text

Identifiers

PMID: 27056998
DOI: 10.1093/annonc/mdw163
PMCID: PMC4922319

Genes

RET
ALK
ROS1
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.PMID 27056998Read ↗

A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non–Small-Cell Lung Cancer Patients Harboring ROS1 Gene RearrangementsSemantic proximity Read ↗

RET-rearranged non-small-cell lung cancer and therapeutic implications.Semantic proximity Read ↗

Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non--Small-Cell Lung Cancer.Semantic proximity Read ↗

Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.Semantic proximity Read ↗

Current management of RET rearranged non-small cell lung cancerSemantic proximity Read ↗

Treatment of non–small cell lung cancer with RET rearrangementsSemantic proximity Read ↗

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.Semantic proximity Read ↗

Efficacy of Pemetrexed-based Chemotherapy in Comparison to Non-Pemetrexed-based Chemotherapy in Advanced, ALK+ Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study.Semantic proximity Read ↗

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations.Semantic proximity Read ↗

Favorable clinical outcomes of pemetrexed treatment in anaplastic lymphoma kinase positive non-small-cell lung cancer.Semantic proximity Read ↗

Therapeutic strategies in RET gene rearranged non-small cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.